TerSera Therapeutics develops and markets single‑product, FDA‑approved medicines for niche, high‑unmet‑need indications such as hormone‑dependent cancers, chronic pain, and endocrine disorders. It pairs each drug with integrated patient‑support services—including insurance navigation, prior‑authorization assistance, copay subsidies, and nurse‑led education—to simplify access and improve treatment outcomes for providers and patients.
Funding
$103.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with certain cancers, chronic pain conditions, or hormonal disorders often face limited or no approved therapeutic options and encounter complex insurance and reimbursement barriers that impede timely access to treatment.
Solution
TerSera Therapeutics focuses on identifying and advancing therapeutics with untapped potential for these underserved indications. The company brings to market a portfolio of single‑product medicines—such as ZOLADEX® (goserelin), MARGENZA® (mifepristone), XERMEL0® (ziconotide), and VARUBI® (somatostatin analog)—that address specific disease pathways where alternatives are scarce. In parallel, TerSera provides integrated patient‑support services, including insurance benefit investigations, prior‑authorization assistance, copay subsidies, and dedicated nurse‑led education programs, to streamline access and adherence. By combining science‑driven drug development with comprehensive support infrastructure, TerSera aims to deliver measurable health outcomes for patients and reduce administrative burden for providers.
Target Audience
Primary customers are healthcare providers (oncologists, pain specialists, endocrinologists) and their patients who require specialized therapies and assistance navigating reimbursement and treatment logistics.
Features
- Proprietary development of “one‑and‑only” therapeutics targeting niche indications with high unmet need
- FDA‑approved products for hormone‑dependent cancers, chronic pain, and endocrine disorders
- TerSera SupportSource: insurance navigation, prior‑authorization, appeals, coding, billing, and copay assistance
- TerSera NurseSupport: free enrollment for dedicated nursing specialists who guide patients through treatment initiation and monitoring
- Patient Assistance Program offering free medication for eligible individuals lacking insurance coverage
- Comprehensive prescribing information and safety resources accessible via product‑specific websites
- Real‑world evidence generation and publication to inform clinical practice and guideline inclusion